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Abstract
Background: Fragile X syndrome is the most common genetic disorder of intellectual developmental disorder/
mental retardation (IDD/MR). The prevalence of FXS in a Chinese IDD children seeking diagnosis/treatment in
mainland China is unknown.
Methods: Patients with unknown moderate to severe IDD were recruited from two children’s hospitals. Informed
consent was obtained from the children's parents. The size of the CGG repeat was identified using a commercial
TP-PCR assay. The influence of AGG interruptions on the CGG expansion during maternal transmission was analyzed
in 24 mother-son pairs (10 pairs with 1 AGG and 14 pairs with 2 AGGs).
Results: 553 unrelated patients between six months and eighteen years of age were recruited. Specimens from 540
patients (male:female = 5.2:1) produced high-quality TP-PCR data, resulting in the determination of the FMR1 CGG
repeat number for each. The most common repeat numbers were 29 and 30, and the most frequent interruption
pattern was 2 or 3 AGGs. Five full mutations were identified (1 familial and 4 sporadic IDD patients), and size mosaicism
was apparent in 4 of these FXS patients (4/5 = 80 %). The overall yield of FXS in the IDD cohort was 0.93 % (5/540).
Neither the mean size of CGG expansion (0.20 vs. 0.79, p > 0.05) nor the frequency of CGG expansion (2/10 vs. 9/14,
p > 0.05) was significantly different between the 1 and 2 AGG groups following maternal transmission.
Conclusions: The FMR1 TP-PCR assay generates reliable and sensitive results across a large number of patient
specimens, and is suitable for clinical genetic diagnosis. Using this assay, the prevalence of FXS was 0.93 % in
Chinese children with unknown IDD.
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Background
Intellectual developmental disorder/mental retardation
(IDD/MR) encompasses a cluster of symptoms that are
characterized by low intelligence and limitations in
adaptive behavior and functional capabilities [1, 2]. Gen-
erally, IDD occurs in approximately 1-3 % of individuals
worldwide, with an incidence of 1 % in high income
countries and 2 % in low/middle income countries [3, 4].
Genetic/genomic factors are a major risk factor for
IDD, accounting for 85 % of patients with IDD [5].
Among them, fragile X syndrome (FXS, MIM 309550) is
the most common form of IDD. The prevalence of FXS
is estimated to be 1/4,000 in males and 1/5,000-8000 in
females [6, 7]. FXS accounts for approximately 20 % of
patients with X-linked IDD [8] and 2–7 % of children
with autism [9, 10]. However, the classic facial features
of FXS (prominent forehead, a long narrow face, pro-
truding ears, and macroorchidism) are ambiguous until
juvenile development, and neurophysical symptoms are
also subtle in young children [11]. The lack of a clear
phenotype in young children can delay a definitive diag-
nosis, leading to a diagnostic “odyssey” for families and a
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delay in the implementation of specific therapies. Indeed,
it has been reported that in the USA up to 40 % of families
with FXS girls and 25 % with FXS boys have had another
child before their first affected child was diagnosed [12].
Additionally, only a 40 % penetrance for mental impair-
ment is reported in affected females [13, 14], making a clear
clinical diagnosis even more difficult in girls. Consequently,
identifying children, particularly infants and toddlers with
FXS, is critically dependent on molecular genetics testing.
FXS is typically caused by an expansion of CGG trinu-
cleotides repeats in the 5′ untranslated region of the
FMR1 gene. The most common size of CGG repeats
among the general population is 29 and 30 copies [15].
In FXS patients, the CGG number expands to greater
than 200 repeats, resulting epigenetic silencing of the
FMR1 gene and the absence of the encoded protein, fra-
gile X mental retardation protein (FMRP) [15]. FXS mo-
lecular diagnostic tests include region-specific CGG PCR
amplification and Southern blot (SB) analysis. Recently,
triplet repeat-primed (TP)-PCR methods have been de-
scribed, which simplify FMR1 genotyping and can detect
both full mutation expansions and low-level size mosai-
cism with high sensitivity [16, 17].
The prevalence of FXS in a Chinese IDD population
has been previously reported [18, 19] However, the rate
of FXS in IDD children seeking diagnosis/treatment in
mainland China is unknown. The availability of such in-
formation is expected to help enhance awareness among
neurologists in suspicious populations and improve op-
tions for intervention and treatment. Herein, we utilized
commercial FMR1 TP-PCR reagents to identify the
prevalence of FXS in Chinese children with unknown
IDD. In addition, the AGG interruption pattern was ana-
lyzed in 24 mother-son pairs to investigate the relation-
ship between the AGG structure and characteristics of
CGG expansion from mother to child.
Methods
Sample recruitment
Patients with unknown moderate to severe IDD (IQ < 55)
were recruited from two children hospitals, namely the
affiliated Children's Hospital of Capital Institute of
Pediatrics and the Peking University First Hospital. The
severity of IDD was scored by the Wechsler Intelligence
Scale for Children (WISC) [20] or the Gesell Developmen-
tal Schedules [21]. DSM-IV criteria were used to indicate
a diagnosis of ASD [22]. The recruited patients met at
least one of the following requirements:
 Male patient with unknown moderate to severe IDD
 In addition to IDD, the presence of other familial
medical problems in the patient’s three-generation
pedigree, such as tremor, ataxia, or premature
ovarian insufficiency
 Evidence of familial IDD. In addition to the proband,
the presence of at least another person with IDD or
other neurodevelopmental disorders in the
three-generation pedigree, including ASD,
developmental delay (e.g., delayed milestones for sitting,
walking, or talking), social or behavior problems,
learning difficulty or language delay, or ADHD
 Suggested facial dysmorphism, such as a long face,
prominent nose and jaw, big ears, thick lip, or other
distinctive physical features such as enlarged testicles
Urine screening (GC-MS) was performed on enrolled
patients to exclude IDD-related metabolic diseases. Any
acquired IDD was also excluded. Of note, this Chinese
IDD cohort was previously profiled using aCGH/multi-
plex ligation-dependent probe amplification (MLPA) and
some targeted sequencing [23–26]. Consequently, patients
with any IDD-related genomic copy number variants or
genomic mutation including subtelomeric aberrations,
16p11.2 microdeletion, 15p11-13 microdeletion or 22q11
microdeletion, or SHANK3 deletion were excluded. Fe-
male patients with Rett Syndrome were also excluded.
Informed consent was obtained from the children's
parents in accordance with the publication of any associ-
ated clinical information and images. This study was ap-
proved by the Capital Institute of Pediatrics and the
Peking University First Hospital Review Board.
DNA extraction and sex identification
DNA was isolated from peripheral blood using the Blood
and Tissue kit (Qiagen, Valencia, CA,USA) and quantified
with a NanoDrop spectrophotometer (Thermo Scientific,
Erembodegem-Aalst, Belgium). The sex of each sample
was confirmed after evaluation using a sex-specific PCR
assay that targeted the AMEL and SRY alleles (Additional
file 1: Table S1).
FMR1 Region-specific CGG PCR
Primers covering the FMR1 promoter region (Additional
file 1: Table S1) were designed to amplify the CGG repeat
segment. A modified protocol containing PCR enhancer
solution (Life Technology, Grand Island, NY, USA) was
used to amplify this GC-rich region. The PCR products
were purified (Exonuclease I, New England Biolabs, Ips-
wich, MA, USA) and sequenced using the standard proto-
col (BigDye, Applied Biosystems, Foster City, CA, USA).
Raw sequences were visualized by Mutation Surveyor
V3.30 (SoftGenetics, State College, PA, USA) and blasted
to the human reference sequence (http://genome.ucsc.edu/,
hg19) to determine the CGG repeat number.
FMR1 triplet repeat-primed (TP)–PCR
The diluted DNA sample (40 ng/ul) was amplified using
AmplideX® FMR1 PCR reagents (Asuragen, Austin, TX,
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USA). The PCR product was stored at −20 °C and pro-
tected from light before fragment sizing. A 3730xl Genetic
Analyzer (Applied Biosystems, Vernon Hills, Illinois, USA)
running POP-7 polymer on a 36 cm capillary was used to
analyze the amplicon size. A total of 2 ul of unpurified PCR
product was mixed with 11 ul Hi-Di Formamide and 2 ul
ROX 1000 Size Ladder prior to injection. The raw sequence
data was uploaded to GeneMapper 4.0 software (Applied
Biosystems, Vernon Hills, Illinois, USA). The size of the
PCR product was converted to the repeat number using an
MS Excel-based data analysis macro. A mixed internal
standard DNA sample was tested in the same plate for each
experiment to provide a process control.
Samples were categorized by repeat size as follows.
13–44 CGG repeats were indicated as normal, 45–54 re-
peats as intermediate, and 55–200 CGG repeats as premu-
tation. Greater than 200 CGG repeats was flagged as full
mutation [6]. Six male samples with known CGG repeats
(13, 29, 31, 32, 43), and two samples with premutation or
full mutation (a gift from Prof. Kun Xia, Central South
University, Changsha, China) were assessed as independ-
ently genotyped controls. These controls were analyzed by
both the FMR1 region-specific CGG PCR and TP-PCR.
AGG interruption status, and assessments of maternal
transmission to the next generation
Maternal transmissions of CGG repeat alleles were de-
termined in 24 mother-son pairs with different AGG
structures. The AGG interruption pattern was deduced
from the electropherogram pattern as previously de-
scribed [16], using both parent and child data to recon-
cile any ambiguities in interpretation. Any difference in
the overall CGG repeat (i.e., >0 repeat) between mother
and son indicated CGG expansion following maternal
transmission.
Results
FMR1 Region-specific CGG PCR and TP–PCR produce
concordant CGG sizing results that are in agreement with
known genotypes
We performed both the Region-specific CGG PCR and
TP–PCR assay for seven samples with known CGG
sizes. For samples with CGG repeats in the normal size
range (13–43 CGG), single well-defined amplification
bands were observed on a 2 % agarose gel (Fig. 1a). The
sequencing data from region-specific CGG PCR was
compared with the predicted sizing from TP–PCR; a de-
viation of none or one CGG repeat was observed in each
case, indicating quantitative consistency in repeat sizing
between the two assays. Although the region-specific
CGG PCR failed to amplify the sample with >60 repeats
(a female premutation, Fig. 1a), the TP–PCR accurately
sized this sample (CGG = 31, 69 and 91, Fig. 1b). For the
sample with an FMR1 full mutation, only a very faint
amplicon band was observed from the region-specific
CGG PCR (white arrow in Fig. 1a). However, the TP–PCR
Fig. 1 FMR1 Region-specific CGG PCR and TP-PCR for seven samples with known CGG repeat lengths. a The CGG repeat size of seven samples
with known genotype were analyzed on agarose gel after FMR1 region-specific CGG PCR. CGG sizes as determined by the TP-PCR assay or SB
analysis is shown at the top of the image. For the premutation (PM) female sample, the gel image reveals the normal FMR1 allele on another
chromosome. For the male sample with a full mutation (FM), the weak band (white arrow) indicates size mosaicism. M: DNA maker; NC: negative
control, no DNA for PCR reaction. PCR amplicons from samples with a premutation (b) and full mutation (c) were also analyzed by capillary
electrophoresis following the FMR1 TP-PCR assay. TP–PCR confirmed size mosaicism in the PM sample (69 and 91 repeats) and the FM sample
(30, >200 repeats). This mosaicism was undetected by SB analysis. The black arrow indicates the normal allele, and red arrow indicates the PM
allele. The blue arrow indicates the FM allele. The predicted size of the CGG repeats from TP-PCR is labeled
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reported a full mutation as well as indications of size mo-
saicism (CGG= 30 and >200, Fig. 1b). Of note, the size
mosaicism detected by TP-PCR was not evident by SB
analysis. This is not surprising given the superior sensitiv-
ity of TP-PCR compared to SB analysis [16].
The yield of FMR1 full mutation in Chinese children with
unknown IDD
Samples from 553 unrelated children (male:female = 5.2:1)
with unexplained IDD were analyzed using the FMR1
TP–PCR assay. Samples from 13 children were excluded
from data analysis due to unsatisfactory electropherogram
traces, leaving 540 patient samples for genotyping. The
ratio of isolated IDD and non-isolated IDD was 2.46
(384:156, Table 1); ASD and learning difficulties were
common comorbid phenotypes (28.9 %). The normal
CGG range was 13–45 repeats, and 29 and 30 repeats rep-
resented the most common alleles (62.6 %), consistent
with previous Chinese reports [18, 27–29]. Five full muta-
tions were identified from male cases (one case with fa-
milial IDD, four cases with sporadic IDD). As a result,
the diagnostic yield of FMR1 full mutation in unknown
IDD children was 0.93 % (5/540).
FXS size mosaicism and phenotypic heterogeneity
Size mosaicism was detected in 4 of 5 FXS patients
(80 %), suggesting that CGG size mosaicism is a com-
mon phenomenon in FXS patients. Further, intellectual
phenotypes were distinct among the 5 FXS individuals.
Two patients showed moderate IDD, and whereas 3
demonstrated mild IDD. Three patients also presented
other cognitive impairments (eg, learning difficulty/lan-
guage delay, social dysfunctions). For the sporadic IDD
case, facial features characteristic of FXS were not appar-
ent, but they did have large testes.
FXS size mosaicism and phenotypic heterogeneity was
particularly prominent in one of the families with a his-
tory of IDD (Fig. 2a). The proband in this case study is a
sixteen-year-old boy (III:1) with moderate IDD and
learning difficulties. His mother (II:9) and younger sister
(III:4) showed isolated IDD and his maternal uncles
(II:8, II:12) manifested social and cognitive deficits. Of
note, one uncle (II:8) presented severe social and cogni-
tive dysfunctions. The predominant facial characteristics
of FXS (large nose, big ears and thick lip, and large tes-
tes) were seen only in the proband and his uncle (II:8).
An FMR1 full mutation was detected in the proband, his
mother, his younger sister and two maternal uncles. Size
mosaicism was identified in family members carrying
premutation or full mutation.
The maternal expansion of the CGG repeat was fur-
ther analyzed in II:9 and III:1 (Fig. 2b). The proband’s
mother carries one normal FMR1 allele (CGG = 30, high
blue peak), and three mosaic sizes on her affected allele
(CGG = 32, black arrow; CGG = 150, red arrow; full mu-
tation, blue arrow). Meanwhile, the proband presented
at least two mosaic sizes (CGG = 32, and full mutation).
We surmise that the full mutation in the proband was
inherited and expanded from the maternal premutation.
Alternatively, the mother’s full mutation may be inher-
ited and continued to expand. Any assessment of further
expansion, however, would require slab gel analysis of
the PCR products using a 2-primer configuration of the
AmplideX FMR1 PCR reagents since these full-mutation
amplicons are too large for resolution by CE using the
POP-7 polymer.
Maternal transmissions of CGG repeat in sample with
reduced AGG interruption
AGG sequence interruptions in the CGG repeat segment
of the FMR1 promotor region are known to reduce the
risk of repeat expansion, possibly by stabilizing strand
slippage during DNA replication [30]. For this IDD child
cohort, only 21 non-FXS patients had less than two
AGG interruptions (21/540 = 3.9 %). This value is similar
to previous reports in Chinese populations [29, 31]. Fol-
lowing clinical review and maternal consent, 24 mother-
son DNA pairs were available to explore the relationship
between AGG interruption and maternal CGG expan-
sion. We subgrouped these 24 samples by AGG inter-
ruption status (ten pairs with AGG = 1, fourteen pairs
with AGG = 2; see Table 2). Following statistical analysis,
the mean maternal CGG repeat was not significantly dif-
ferent between the two groups (29 vs. 30.2, p > 0.05).
Table 1 Clinical information and FMR1 genotypes of 540 children with unknown IDD
IDD children Category N (male/female) FXS yield
540 (453/87)
Isolated IDD (without neuro-developmental comorbid) 384 (307/77) 1
Non-isolated IDD * 156(146/10) 4
FMR1 genotyping Category N (male/female) CGG size
Samples with normal repeat 534(447/87) 13-45
Samples with full mutation 5 (5/0) >200
Samples with intermediate status 1 (1/0) 53
* accompanied by other neuro-developmental comorbid phenotypes, including ASD, ADHD, learning difficulty and seizure/epilepsy
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During the maternal transmission, neither the mean size
of CGG expansion (0.20 vs. 0.79, p > 0.05) nor the fre-
quency of CGG expansion (2/10 vs. 9/14, p > 0.05) was
significantly different in two subgroups. Consequently,
our results indicate that there is no difference between 1
and 2 AGGs with respect to repeat length in the next
Fig. 2 The genotypes and phenotypes for a familial FXS. a The pedigree of a classic familial FXS patient (squares indicate males and circles
indicate females). IDD-affected individuals are presented as black symbols while normal individuals are presented as white symbols. The proband
is indicated with an arrow. The facial features of classic FXS, including long face, predominant nose and large jaw, is seen in the proband (III:1)
and his uncle (II:8). b Size mosaicism in affected IDD individuals (II:9 and III:1) identified by TP-PCR. The size of CGG repeats is labeled
underneath the peak
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generation for mothers with normal FMR1 CGG sizes.
This result is consistent with previous findings [32].
Discussion
FMR1 TP-PCR is a rapid and accurate method to diagnose
FXS in IDD children
Historically, SB analysis has been the standard approach
in many clinical laboratories for the molecular diagnosis
of FXS patients. However, this process is both time-
and labor-intensive (with a typical turn-around time of
2 weeks), requires a large input of DNA, and offers poor
resolution to size CGG repeat [16, 33]. Furthermore, SB
has a relatively poor analytical sensitivity to detect ex-
pansions in samples with low-level size mosaicism [34].
For FMR1 region-specific CGG PCR, the high GC con-
tent of the 5′ untranslated segment is refractory to
standard PCR amplification, and usually only <50-100
repeats can be reliably amplified and detected. This in-
ability to reliably identify mid- to large-size expanded al-
leles can produce false negatives, particularly for female
samples where the more likely interpretation of a single
amplicon product after electrophoresis is that the FMR1
allele is homozygous. A further complication is that full-
mutation size mosaicism, seen in 4 of 5 FXS patients in
our study, can present an additional product peak after
PCR that can confound interpretation. Consequently, a
more convenient, sensitive, high resolution and accurate
assay with a shorter turn-around time is needed to im-
prove the molecular diagnosis of patients that are suspi-
cious for FXS or premutation phenotypes.
The sensitivity and uniformity of the FMR1 TP-PCR
has been previously reported [35]. Our study provides
further proof that this single-tube PCR amplification can
accurately size CGG repeats from low-input DNA. The
total turn-around time from DNA dilution to report
acquisition was 48 h, which is considerably less than SB
analysis. Moreover, the TP–PCR assay is sensitive enough
to detect low-level size mosaicism. We conclude that this
FMR1 TP-PCR is appropriate for FXS molecular diagnosis.
The prevalence of FXS in Chinese children with unknown
IDD
The prevalence of FXS in IDD populations is diverse be-
cause both the test method and recruited target populations
are diverse. Recently, Peprah reviewed approximately 45
publications that addressed the FXS prevalence in IDD
populations [15]. The results revealed a 0.5-9.7 % diag-
nostic yield of FXS, with Canadian, Estonian, Japanese,
and Taiwanese groups having the lowest prevalence of
FXS. In addition, countries that don’t routinely perform
FMR1 molecular testing appear to have a significantly
lower prevalence than western countries that do [15]. In
this study, we determined that the prevalence of FXS in
Chinese IDD children is 0.93 % overall, and 1.1 % in
male patients and 0 % in female patients. This FXS
prevalence is lower than that reported from studies in
western counties. A study of 119,232 samples in one
large US reference laboratory revealed that the rate of
FMR1 full mutation was 1.3 %, with 1.4 % for males and
0.61 % for females [36]. Another study comprised of 1755
children with non-specific mental retardation reported
that the overall yield of FXS was about 3.5 % in a Greek
MR cohort [37]. Our study confirmed ethnic differences
in FXS prevalence.
We identified a high prevalence of size mosaicism in
Chinese FXS boys (80 %). Size mosaicism was reported
to be common in FXS patient [38–40]. Such mosaicism
can arise de novo or be passed on by phenotypically-
normal mosaic parents [41, 42]. Recently, an FMR1 mo-
saic deletion was reported in a Chinese FXS boy, which
was initially absent in his phenotypically-normal mother’s
blood. However, an in-depth study of his mother’s FMR1
profile using qPCR and breakpoint mapping-PCR con-
firmed low-level mosaicism in different maternal tissues
(eg, blood, skin, eyebrow, urine sediment and menstrual
discharge) [40]. The maternal inheritance pattern of
FMR1 size mosaicism was also analyzed in the familial
FXS pedigree. Evidence of size mosaicism in the proband,
his mother, his sister and two uncles suggested that his
FMR1 size mosaicism was inherited from his grandfather.
Factors affecting the FXS prevalence in Chinese patient
populations
The FXS yield from the patients in this study is also dif-
ferent from that reported in previous Chinese IDD/MR
populations [18, 19]. Zhong et al. performed multi-
institutional screening of 1127 adult/child individuals
with mild-moderate IDD, and found that 2.8 % of the
Chinese IDD patients carry a full mutation. In this work,
both PCR and SB was performed to exclude full
Table 2 Changes in repeat size during the maternal transmission in 24 mother-son pairs with different AGG structures




Mean of CGG expansion
during maternal transmission**
Number of mother-boy pair
showing CGG expansion (%)
1 10 29 0.20 2 (20 %)
2 14 30.2 0.79 9 (64 %)
* The minimum CGG repeat was determined for mothers with heterozygous FMR1 alleles; ** The maximum CGG expansion was calculated for mothers with
heterozygous FMR1 alleles; * The difference in CGG size between mother and son CGG genotypes. See Supplementary Table 2 for detailed FMR1
genotyping information
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mutation and abnormal methylation [18]. In contrast,
only a 0.6 % FXS yield was reported from 324 Hong
Kong patients with mild mental retardation [19]. For this
cohort, electrophoresis of the fragment from the region-
specific CGG PCR followed by hybridization using a
CGG probe was analyzed to screen FXS. We suspect
that both the screening method used and the severity of
IDD can affect the determination of FXS prevalence.
Further, previous studies have confirmed that FXS ap-
pears to be more prevalent among patients with mild
MR than severe MR [15, 43]. In this study, severe and
moderate IDD accounted for 50 % of recruited patients,
and all FXS patients presented moderate IDD.
Both clinical knowledge and complex comorbidities
for FXS can also affect the assessment of FXS yield. In
China, it is the pediatric neurologist or physician, rather
than the clinical geneticist, that examines patients re-
ferred for a suspected genetic disorder. However, most
Chinese pediatricians, with the exception of some
pediatric specialists, are uninformed about FXS. FXS
presents a challenging clinical diagnosis based on the
fact that the classic facial features of FXS are ambiguous
until juvenile development, and that the cognitive pres-
entation of FXS can be subtle in young children [11].
Recently, Li et al. performed a study surveying the FXS
knowledge and attitudes of Chinese medical college
students [44]. He found that less than one-third of the par-
ticipants were aware of FXS. This investigation highlights
both the challenges and opportunities of genetic education
in China. Additionally, many neuro-developmental disor-
ders can occur as major symptoms or comorbid pheno-
types in FXS patients. Since a detailed score checklist for
FXS testing from GeneReviewers (http://www.ncbi.nlm.
nih.gov/books/NBK1384/) was not provided, it would be
difficult for pediatrician to distinguish FXS from other
possible neuro-developmental disorders. Also, other
genomic common copy number variants or rare single
nucleotide variants can contribute to variable neuro-
developmental traits in FXS [7, 45]. In the future, further
background on FXS should be provided to the clinicians.
These actions may increase the yield of FXS, perhaps up
to 4 % as recently reported [46].
The role of AGG interruption on maternal FMR1 CGG
expansion
Generally, the normal CGG repeat harbors 2 or 3 AGGs,
whereas premutations and full mutations present 0 or 1
AGG [47]. The number of AGGs in the 5’ region was
correlated with repeat instability during maternal trans-
mission [32, 47, 48]. Recent studies have demonstrated
that women with greater than 54 repeats and no AGG
have an elevated risk for expansion to a full mutation in
the next generation [32]; However, maternal alleles with
<45 repeats rarely expanded, even when they had no or
only 1 AGG interruption [32]. In this study, 24 mothers
had CGG repeats of <54, and thus our finding that none
of these alleles significantly expanded after transmission
is consistent with previous reports.
Limitations of FMR1 TP-PCR for FXS molecular diagnosis
Over 98 % of FXS is caused by CGG expansions. The
remaining cases are attributed to deletions or point vari-
ants in the FMR1 region [49–54]. The ACMG recom-
mends that FMR1 copy number variants and sequencing
of FMR1 coding regions be performed to exclude pos-
sible FMR1 deletions or point mutations [6] for suspi-
cious cases without repeat expansions. In addition, the
abnormal methylation status of the FMR1 may be asso-
ciated with FXS [36]. Both deletion/point variants and
methylation status of FMR1 may evade detection by TP-
PCR, but methylation analysis can be performed using a
separate PCR-based method [34]. Consequently, the above
testing is necessary for patients with negative TP-PCR
results that are highly suspect for FXS.
Conclusions
In summary, the FMR1 TP-PCR assay can accurately
and sensitively quantify and classify CGG repeats with a
rapid turn-around time. Using this methodology, we
established an incidence of 0.93 % FXS in a Chinese
children with unknown IDD, and found that size mosai-
cism was common (80 %) in the 5 patients fragile X full
mutations.
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